300858 科拓生物
已收盘 12-19 15:00:00
资讯
新帖
简况
12月13日科拓生物发布公告,其股东减持263.5万股
证券之星 · 12-13
12月13日科拓生物发布公告,其股东减持263.5万股
科拓生物(300858)12月6日主力资金净买入606.86万元
证券之星 · 12-06
科拓生物(300858)12月6日主力资金净买入606.86万元
12月5日科拓生物涨6.55%,鹏华新兴产业混合基金重仓该股
证券之星 · 12-05
12月5日科拓生物涨6.55%,鹏华新兴产业混合基金重仓该股
科拓生物11月29日现2笔大宗交易 成交金额1200万元
新浪证券-红岸工作室 · 11-29
科拓生物11月29日现2笔大宗交易 成交金额1200万元
11月29日科拓生物现1200万元大宗交易
证券之星 · 11-29
11月29日科拓生物现1200万元大宗交易
11月26日科拓生物涨8.05%,鹏华新兴产业混合基金重仓该股
证券之星 · 11-26
11月26日科拓生物涨8.05%,鹏华新兴产业混合基金重仓该股
科拓生物:关于非独立董事辞职的公告
新浪财经-鹰眼工作室 · 11-25
科拓生物:关于非独立董事辞职的公告
图解科拓生物三季报:第三季度单季净利润同比减12.62%
证券之星 · 10-30
图解科拓生物三季报:第三季度单季净利润同比减12.62%
科拓生物(300858.SZ)部分股东拟合计减持不超4%股份
智通财经网 · 10-28
科拓生物(300858.SZ)部分股东拟合计减持不超4%股份
科拓生物最新公告:两名股东拟合计减持公司不超4%股份
证券之星 · 10-27
科拓生物最新公告:两名股东拟合计减持公司不超4%股份
科拓生物(300858)10月25日主力资金净卖出1759.09万元
证券之星 · 10-25
科拓生物(300858)10月25日主力资金净卖出1759.09万元
10月24日科拓生物涨5.14%,鹏华新兴产业混合基金重仓该股
证券之星 · 10-24
10月24日科拓生物涨5.14%,鹏华新兴产业混合基金重仓该股
科拓生物涨5.14%,东吴证券二个月前给出“买入”评级
证券之星 · 10-24
科拓生物涨5.14%,东吴证券二个月前给出“买入”评级
10月11日科拓生物跌5.09%,鹏华新兴产业混合基金重仓该股
证券之星 · 10-11
10月11日科拓生物跌5.09%,鹏华新兴产业混合基金重仓该股
9月27日科拓生物涨5.82%,鹏华新兴产业混合基金重仓该股
证券之星 · 09-27
9月27日科拓生物涨5.82%,鹏华新兴产业混合基金重仓该股
科拓生物涨5.82%,东吴证券一个月前给出“买入”评级
证券之星 · 09-27
科拓生物涨5.82%,东吴证券一个月前给出“买入”评级
科拓生物(300858)9月12日主力资金净卖出106.35万元
证券之星 · 09-12
科拓生物(300858)9月12日主力资金净卖出106.35万元
科拓生物(300858)8月23日主力资金净买入130.06万元
证券之星 · 08-23
科拓生物(300858)8月23日主力资金净买入130.06万元
科拓生物(300858)2024年中报简析:净利润增7.89%,盈利能力上升
证券之星 · 08-22
科拓生物(300858)2024年中报简析:净利润增7.89%,盈利能力上升
东吴证券:给予科拓生物买入评级
证券之星 · 08-22
东吴证券:给予科拓生物买入评级
公司概况
公司名称:
北京科拓恒通生物技术股份有限公司
所属行业:
食品制造业
上市日期:
2020-07-27
主营业务:
北京科拓恒通生物技术股份有限公司的主营业务是从事复配食品添加剂、食用益生菌制品以及动植物微生态制剂研发、生产与销售。公司的主要产品分为食用益生菌原料菌粉、即食型复合益生菌固体饮料、发酵剂、生物保鲜剂等。公司是中关村高新技术企业,同时也是北京市“专精特新”中小企业、北京市知识产权试点单位。
发行价格:
23.70
{"stockData":{"symbol":"300858","market":"SZ","secType":"STK","nameCN":"科拓生物","latestPrice":15.8,"timestamp":1734591789000,"preClose":15.7,"halted":0,"volume":3889969,"delay":0,"floatShares":194000000,"shares":263000000,"eps":0.3517,"marketStatus":"已收盘","marketStatusCode":5,"change":0.1,"latestTime":"12-19 15:00:00","open":15.55,"high":16.03,"low":15.23,"amount":60591500,"amplitude":0.051,"askPrice":15.8,"askSize":26,"bidPrice":15.79,"bidSize":21,"shortable":0,"etf":0,"ttmEps":0.3517,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"adjPreClose":15.7,"symbolType":"stock","openAndCloseTimeList":[[1734571800000,1734579000000],[1734584400000,1734591600000]],"highLimit":17.27,"lowLimit":14.13,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":263495118,"pbRate":2.34,"roa":"--","roe":"4.06%","epsLYR":0.35,"committee":-0.082209,"marketValue":4163000000,"floatMarketCap":3061000000,"peRate":44.924651,"changeRate":0.0064,"turnoverRate":0.0201,"status":0},"requestUrl":"/m/hq/s/300858/wiki","defaultTab":"wiki","newsList":[{"id":"2491329177","title":"12月13日科拓生物发布公告,其股东减持263.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491329177","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491329177?lang=zh_cn&edition=full","pubTime":"2024-12-13 20:01","pubTimestamp":1734091284,"startTime":"0","endTime":"0","summary":"证券之星消息,12月13日科拓生物发布公告《科拓生物:关于持股5%以上股东权益变动达到1%的公告》,其股东宁波科融达创业投资合伙企业(有限合伙)于2024年11月29日至2024年12月12日间合计减持263.5万股,占公司目前总股本的1.0%,变动期间该股股价上涨7.95%,截止12月12日收盘报17.51元。股东增减持详情见下表:根据科拓生物2024年三季报公布的十大股东详情如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121300041379.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2489472064","title":"科拓生物(300858)12月6日主力资金净买入606.86万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489472064","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489472064?lang=zh_cn&edition=full","pubTime":"2024-12-06 15:29","pubTimestamp":1733470197,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年12月6日收盘,科拓生物报收于17.21元,下跌2.05%,换手率3.83%,成交量7.43万手,成交额1.27亿元。科拓生物主营业务:从事复配食品添加剂、食用益生菌制品以及动植物微生态制剂研发、生产与销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120600020444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2489481649","title":"12月5日科拓生物涨6.55%,鹏华新兴产业混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2489481649","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489481649?lang=zh_cn&edition=full","pubTime":"2024-12-05 16:14","pubTimestamp":1733386449,"startTime":"0","endTime":"0","summary":"证券之星消息,12月5日科拓生物涨6.55%,收盘报17.57元,换手率6.06%,成交量11.75万手,成交额2.0亿元。根据2024基金Q3季报公募基金重仓股数据,重仓该股的公募基金共9家,其中持有数量最多的公募基金为鹏华新兴产业混合。鹏华新兴产业混合目前规模为29.83亿元,最新净值2.635,较上一交易日下跌0.68%,近一年下跌2.73%。鹏华新兴产业混合的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120500026022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2487553332","title":"科拓生物11月29日现2笔大宗交易 成交金额1200万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2487553332","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487553332?lang=zh_cn&edition=full","pubTime":"2024-11-29 17:00","pubTimestamp":1732870800,"startTime":"0","endTime":"0","summary":" 11月29日,科拓生物收涨1.54%,收盘价为16.47元,发生2笔大宗交易,合计成交量80万股,成交金额1200万元。 进一步统计,近3个月内该股累计发生2笔大宗交易,合计成交金额为1200万元。该股近5个交易日累计上涨11.28%,主力资金合计净流入1054.2万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-29/doc-incxtqvq8635919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2487358074","title":"11月29日科拓生物现1200万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2487358074","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487358074?lang=zh_cn&edition=full","pubTime":"2024-11-29 16:49","pubTimestamp":1732870166,"startTime":"0","endTime":"0","summary":"证券之星消息,11月29日科拓生物发生大宗交易,交易数据如下:近三个月该股共发生2笔大宗交易,合计成交8000.0手,折价成交2笔。该股近期无解禁股上市。截至2024年11月29日收盘,科拓生物(300858)报收于16.47元,上涨1.54%,换手率3.71%,成交量7.19万手,成交额1.19亿元。该股最近90天内共有1家机构给出评级,买入评级1家。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112900024779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2486028829","title":"11月26日科拓生物涨8.05%,鹏华新兴产业混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2486028829","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486028829?lang=zh_cn&edition=full","pubTime":"2024-11-26 16:13","pubTimestamp":1732608783,"startTime":"0","endTime":"0","summary":"证券之星消息,11月26日科拓生物涨8.05%,收盘报16.37元,换手率4.72%,成交量9.15万手,成交额1.46亿元。重仓科拓生物的公募基金请见下表:根据2024基金Q3季报公募基金重仓股数据,重仓该股的公募基金共9家,其中持有数量最多的公募基金为鹏华新兴产业混合。鹏华新兴产业混合的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112600026524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300858"],"gpt_icon":0},{"id":"2486705285","title":"科拓生物:关于非独立董事辞职的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2486705285","media":"新浪财经-鹰眼工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486705285?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:40","pubTimestamp":1732527600,"startTime":"0","endTime":"0","summary":"北京科拓恒通生物技术股份有限公司关于非独立董事辞职的公告本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗漏。北京科拓恒通生物技术股份有限公司董事会于近日收到非独立董事林伟先生提交的书面辞任报告,林伟先生因个人原因辞去公司第三届董事会董事及董事会审计委员会委员职务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-25/doc-incxhqmk8144165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0226","300858"],"gpt_icon":0},{"id":"2479223211","title":"图解科拓生物三季报:第三季度单季净利润同比减12.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479223211","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479223211?lang=zh_cn&edition=full","pubTime":"2024-10-30 01:39","pubTimestamp":1730223548,"startTime":"0","endTime":"0","summary":"证券之星消息,科拓生物2024年三季报显示,公司主营收入2.19亿元,同比上升0.81%;归母净利润7119.09万元,同比下降1.13%;扣非净利润6109.79万元,同比上升0.3%;其中2024年第三季度,公司单季度主营收入8066.41万元,同比上升4.74%;单季度归母净利润2767.59万元,同比下降12.62%;单季度扣非净利润2346.12万元,同比下降18.62%;负债率4.65%,投资收益185.47万元,财务费用-1980.14万元,毛利率54.14%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000001170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858"],"gpt_icon":0},{"id":"2478183001","title":"科拓生物(300858.SZ)部分股东拟合计减持不超4%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2478183001","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478183001?lang=zh_cn&edition=full","pubTime":"2024-10-28 07:44","pubTimestamp":1730072669,"startTime":"0","endTime":"0","summary":"智通财经APP讯,科拓生物(300858.SZ)公告,公司持股5%以上股东宁波科融达创业投资合伙企业(有限合伙)(更名前名称:北京科融达投资合伙企业(有限合伙),简称“科融达”)、股东宁波科汇达创业投资合伙企业(有限合伙)(更名前名称:北京科汇达投资合伙企业(有限合伙),简称“科汇达”)计划合计减持公司股份不超过1053.98万股,即不超过公司股份总数的4%。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1200891.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0226","300858"],"gpt_icon":0},{"id":"2478876168","title":"科拓生物最新公告:两名股东拟合计减持公司不超4%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2478876168","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478876168?lang=zh_cn&edition=full","pubTime":"2024-10-27 21:10","pubTimestamp":1730034601,"startTime":"0","endTime":"0","summary":"科拓生物公告,公司股东科融达、科汇达拟分别计划减持公司股份数量不超过526.99万股,即不超过公司股份总数的2%。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102700014603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300858"],"gpt_icon":0},{"id":"2478676391","title":"科拓生物(300858)10月25日主力资金净卖出1759.09万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478676391","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478676391?lang=zh_cn&edition=full","pubTime":"2024-10-25 15:21","pubTimestamp":1729840893,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年10月25日收盘,科拓生物报收于15.96元,下跌1.18%,换手率2.8%,成交量5.43万手,成交额8666.6万元。科拓生物主营业务:从事复配食品添加剂、食用益生菌制品以及动植物微生态制剂研发、生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500020088.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300858"],"gpt_icon":0},{"id":"2477957777","title":"10月24日科拓生物涨5.14%,鹏华新兴产业混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2477957777","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477957777?lang=zh_cn&edition=full","pubTime":"2024-10-24 16:16","pubTimestamp":1729757771,"startTime":"0","endTime":"0","summary":"证券之星消息,10月24日科拓生物涨5.14%,收盘报16.15元,换手率3.9%,成交量7.56万手,成交额1.22亿元。根据2024基金Q3季报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为鹏华新兴产业混合。鹏华新兴产业混合目前规模为29.83亿元,最新净值2.675,较上一交易日下跌0.63%,近一年上涨2.85%。鹏华新兴产业混合的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102400025591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2477577009","title":"科拓生物涨5.14%,东吴证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2477577009","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477577009?lang=zh_cn&edition=full","pubTime":"2024-10-24 16:16","pubTimestamp":1729757763,"startTime":"0","endTime":"0","summary":"今日科拓生物(300858)涨5.14%,收盘报16.15元。2024年8月22日,东吴证券研究员孙瑜,周韵发布了对科拓生物的研报《2024H1业绩点评:加速战略转型,益生菌业务稳健增长》,该研报对科拓生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为78.73%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为东吴证券的周韵、孙瑜。科拓生物(300858)个股概况:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102400025588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","300858"],"gpt_icon":0},{"id":"2474575780","title":"10月11日科拓生物跌5.09%,鹏华新兴产业混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2474575780","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474575780?lang=zh_cn&edition=full","pubTime":"2024-10-11 16:38","pubTimestamp":1728635927,"startTime":"0","endTime":"0","summary":"证券之星消息,10月11日科拓生物跌5.09%,收盘报14.92元,换手率1.72%,成交量3.32万手,成交额5056.38万元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共8家,其中持有数量最多的公募基金为鹏华新兴产业混合。鹏华新兴产业混合目前规模为27.39亿元,最新净值2.738,较上一交易日上涨0.51%,近一年下跌0.47%。鹏华新兴产业混合的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101100024250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2470774777","title":"9月27日科拓生物涨5.82%,鹏华新兴产业混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2470774777","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470774777?lang=zh_cn&edition=full","pubTime":"2024-09-27 17:14","pubTimestamp":1727428472,"startTime":"0","endTime":"0","summary":"证券之星消息,9月27日科拓生物涨5.82%创60日新高,收盘报15.28元,换手率1.73%,成交量3.36万手,成交额5096.1万元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共8家,其中持有数量最多的公募基金为鹏华新兴产业混合。鹏华新兴产业混合目前规模为27.39亿元,最新净值2.398,较上一交易日上涨2.74%,近一年下跌13.21%。鹏华新兴产业混合的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092700026360.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2470774737","title":"科拓生物涨5.82%,东吴证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2470774737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470774737?lang=zh_cn&edition=full","pubTime":"2024-09-27 17:14","pubTimestamp":1727428466,"startTime":"0","endTime":"0","summary":"今日科拓生物(300858)涨5.82%,收盘报15.28元。2024年8月22日,东吴证券研究员孙瑜,周韵发布了对科拓生物的研报《2024H1业绩点评:加速战略转型,益生菌业务稳健增长》,该研报对科拓生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为78.73%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为东吴证券的周韵、孙瑜。科拓生物(300858)个股概况:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092700026357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","300858"],"gpt_icon":0},{"id":"2466244681","title":"科拓生物(300858)9月12日主力资金净卖出106.35万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2466244681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466244681?lang=zh_cn&edition=full","pubTime":"2024-09-12 15:25","pubTimestamp":1726125944,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年9月12日收盘,科拓生物报收于13.53元,下跌2.52%,换手率0.31%,成交量6002.0手,成交额824.3万元。科拓生物主营业务:从事复配食品添加剂、食用益生菌制品以及动植物微生态制剂研发、生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091200018869.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2461558329","title":"科拓生物(300858)8月23日主力资金净买入130.06万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461558329","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461558329?lang=zh_cn&edition=full","pubTime":"2024-08-23 15:26","pubTimestamp":1724397998,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月23日收盘,科拓生物报收于13.7元,下跌4.2%,换手率0.95%,成交量1.84万手,成交额2517.87万元。科拓生物主营业务:从事复配食品添加剂、食用益生菌制品以及动植物微生态制剂研发、生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300021224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858","BK0226"],"gpt_icon":0},{"id":"2461802535","title":"科拓生物(300858)2024年中报简析:净利润增7.89%,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2461802535","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461802535?lang=zh_cn&edition=full","pubTime":"2024-08-22 06:08","pubTimestamp":1724278109,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期科拓生物发布2024年中报。截至本报告期末,公司营业总收入1.38亿元,同比下降1.34%,归母净利润4351.5万元,同比上升7.89%。本报告期科拓生物盈利能力上升,毛利率同比增幅5.88%,净利率同比增幅9.36%。预付款项变动幅度为158.89%,原因:本报告期末预付采购款增加。其他应付款变动幅度为476.92%,原因:本报告期计提尚未支付的部分股利分红款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082200005146.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300858"],"gpt_icon":0},{"id":"2461721738","title":"东吴证券:给予科拓生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2461721738","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461721738?lang=zh_cn&edition=full","pubTime":"2024-08-22 02:35","pubTimestamp":1724265317,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司孙瑜,周韵近期对科拓生物进行研究并发布了研究报告《2024H1业绩点评:加速战略转型,益生菌业务稳健增长》,本报告对科拓生物给出买入评级,当前股价为14.12元。24H1公司收入低于预期,利润符合预期。24H1公司复配添加剂业务毛利率下滑预计主因收入下降后规模效应减弱+下游客户有所调价。最新盈利预测明细如下:该股最近90天内共有1家机构给出评级,买入评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082200002983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","300858"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-07-27","address":"北京市怀柔区雁栖经济开发区牤牛河路31号院1号-2","stockEarnings":[{"period":"1week","weight":-0.0977},{"period":"1month","weight":0.0347},{"period":"3month","weight":0.1626},{"period":"6month","weight":0.0077},{"period":"1year","weight":-0.1585},{"period":"ytd","weight":-0.1729}],"companyName":"北京科拓恒通生物技术股份有限公司","boardCode":"AI0014","perCapita":"20659股","boardName":"食品制造业","registeredCapital":"26349万元","compareEarnings":[{"period":"1week","weight":-0.0264},{"period":"1month","weight":0.0072},{"period":"3month","weight":0.2314},{"period":"6month","weight":0.124},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1328}],"survey":" 北京科拓恒通生物技术股份有限公司的主营业务是从事复配食品添加剂、食用益生菌制品以及动植物微生态制剂研发、生产与销售。公司的主要产品分为食用益生菌原料菌粉、即食型复合益生菌固体饮料、发酵剂、生物保鲜剂等。公司是中关村高新技术企业,同时也是北京市“专精特新”中小企业、北京市知识产权试点单位。","serverTime":1734625956569,"listedPrice":23.7,"stockholders":"9379人(较上一季度增加2.37%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科拓生物(300858)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科拓生物(300858)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科拓生物,300858,科拓生物股票,科拓生物股票老虎,科拓生物股票老虎国际,科拓生物行情,科拓生物股票行情,科拓生物股价,科拓生物股市,科拓生物股票价格,科拓生物股票交易,科拓生物股票购买,科拓生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科拓生物(300858)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科拓生物(300858)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}